Cas:144147-04-6 5-fluoro-4-methylquinoline manufacturer & supplier

We serve Chemical Name:5-fluoro-4-methylquinoline CAS:144147-04-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

5-fluoro-4-methylquinoline

Chemical Name:5-fluoro-4-methylquinoline
CAS.NO:144147-04-6
Synonyms:5-FLUORO-4-METHYL-QUINOLINE;Quinoline,5-fluoro-4-methyl
Molecular Formula:C10H8FN
Molecular Weight:161.17600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:12.89000
Exact Mass:161.06400
LogP:2.68230

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 5-FLUORO-4-METHYL-QUINOLINE chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Quinoline,5-fluoro-4-methyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-FLUORO-4-METHYL-QUINOLINE Use and application,5-FLUORO-4-METHYL-QUINOLINE technical grade,usp/ep/jp grade.


Related News: As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 5-fluoro-4-methylquinoline manufacturer No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 5-fluoro-4-methylquinoline supplier No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel. 5-fluoro-4-methylquinoline vendor As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 5-fluoro-4-methylquinoline factory No amount of unmet need can take the place of sufficient evidence, said Johns Hopkins public health professor Dr. Caleb Alexander, a member of the FDA advisory panel.